Matrix metalloproteinase 2, 3, and 9 gene polymorphisms in women with rheumatoid arthritis


Cite item

Full Text

Abstract

Aim. To study the promoter regions of the matrix metalloproteinase (MMP)2, MMP3, and MMP9 genes to assess their associations with the risk of rheumatoid arthritis (RA) and with the types of its clinical course in women. Subjects and methods. 162 female patients with RA and 329 women without this condition were examined. Polymorphisms in the gene promoter region for MMP2 (-1306 С→Т), MMP3 (-1171 5A→6А), and MMP9 (-1562 С→Т) were studied. Genotyping was carried out using the restriction fragment length polymorphism method. Results. In the RA group, the -1306TT genotype of MMP2 was significantly more frequently encountered and the 6A6A genotype was less frequently seen. In the seropositive RA group, the frequency of the -1306ТТ genotype of MMP2 was significantly higher than that in the healthy individuals. The significant differences shown for the entire group of patients with RA were preserved when they were divided into groups according to the presence or absence of rheumatoid nodules. Furthermore, the frequency of the homozygous -1306 genotypes of MMP2 was higher in both groups than in the healthy individuals. Conclusion. The presence of the allelic variants of the MMP genes may be one of the genetic factors that predispose to RA in women.

References

  1. Korczowska I. Rheumatoid arthritis susceptibility genes: An overview. World J Orthop. 2014;5(4):544-549.
  2. Furst DE, Emery P. Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatology. 2014;53(9):1560-1569.
  3. Nishikaku AS, Ribeiro LC, Molina RF et al. Matrix metalloproteinases with gelatinolytic activity induced by Paracoccidioides brasiliensis infection. Int J Exp Pathol. 2009;90(5):527-537.
  4. Butler GS, Overall CM. Updated biological roles for matrix metalloproteinases and new «intracellular» substrates revealed by degradomics. Biochemistry. 2009;48(46):10830-10845.
  5. Ribbens C, Andre B, Jaspar JM et al. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol. 2000;27:888-893.
  6. Kobayashi A, Naito S, Enomoto H et al. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med. 2007;131(4):563-570.
  7. Mahmoud RK, El-Ansary AK, El-Eishi HH et al. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis. Ital J Biochem. 2005;54(3-4):248-257.
  8. Giannelli G, Erriquez R, Iannone F et al. MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol. 2004;22(3):335-338.
  9. Konttinen YT, Ceponis A, Takagi M et al. New collagenolytic enzymes/cascade identified at the pannus-hard tissue junction in rheumatoid arthritis: destruction from above. Matrix Biol. 1998;17:585-601.
  10. Yoshida W, Uzuki M, Nishida J et al. Examination of in vivo gelatinolytic activity in rheumatoid arthritis synovial tissue using newly developed in situ zymography and image analyzer. Clin Exp Rheumatol. 2009;27(4):587-593.
  11. Goldbach-Mansky R, Lee JM, Hoxworth JM et al. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis. Arthritis Res. 2000;2(2):145-153.
  12. Zhang B, Herrmann SM, Eriksson P, de Maat M et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999;99:1788-1794.
  13. Насонов Е.Л. Ревматология: национальное руководство. М.: ГЭОТАР-Медиа; 2008.
  14. Arnett FC, Edworthy SM, Bloch D et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum. 1988;31:315-324.
  15. Шевченко А.В., Голованова О.В., Коненков В.И. и др. Анализ полиморфизма генов матриксных металлопротеиназ-2 и -9 у пациентов с ишемической болезнью сердца. Терапевтический архив. 2010;82(1):31-35.
  16. Takahashi M, Haro H, Wakabayashi Y et al. The association of degeneration of the intervertebral disc with 5a/6a polymorphism in the promoter of the human matrix metalloproteinase-3 gene. J Bone Joint Surg. 2001;83(B):491-495.
  17. Бабич П.Н., Чубенко А.В., Лапач С.Н. Применение современных статистических методов в практике клинических исследований. Сообщение третье. Отношение шансов: понятия, вычисление и интерпретация. Украинский медицинский журнал. 2005;46(2):113-119.
  18. Вейр Б. Анализ генетических данных. Дискретные генетические признаки. Пер. с англ. М.: Мир; 1995.
  19. Гланц С. Медико-биологическая статистика. Пер. с англ. М.: Практика; 1998.
  20. Constantin A, Lauwers-Cance`s V, Navaux F et al. A Cantagrel Stromelysin 1 (Matrix Metalloproteinase 3) and HLA-DRB1 Gene Polymorphisms Association With Severity and Progression of Rheumatoid Arthritis in a Prospective Study. Arthritis Rheum. 2002;46(7):1754-1762.
  21. Scherer S, de Souza TB, de Paoli J et al. Matrix metalloproteinase gene polymorphisms in patients with rheumatoid arthritis. Rheumatol Int. 2010;30(3):369-373.
  22. Kim JS, Park HY, Kwon JH et al. The roles of stromelysin-1 and the gelatinase Bgene polymorphism in stable angina. Yonsei Med J. 2002;43:473-481.
  23. Feng Z, He G, Chen Z et al. Lack of association of matrix metalloproteinase-3 gene polymorphism with susceptibility to rheumatoid arthritis: a meta-analysis. BMC Musculoskeletal Disorders. 2014;15:376. http://www.biomedcentral.com/1471-2474/15/376
  24. Бестаев Д.В., Каратеев Д.Е., Насонов Е.Л. Системные проявления ревматоидного артрита. Научно-практическая ревматология. 2013;51(1):76-80.
  25. Nemec P, Pavkova-Goldbergová M, Swobodnik T et al. Polymorphism of gene promotor region for MMP-2 in rheumatoid arthritis. Vnitr Lek. 2006;52(4):348-354.
  26. Sharma A, Singh A, Singh S et al. Evolving clinical profile of HLA-DRB1, MMP1 and NF-Κb gene in rheumatoid factor positive Caucasian population. Int J Cur Sci Res. 2011;1(2):31-34.
  27. Rodriguez-Lopez J, Perez-Pampin E, Gomez-Reino J, Gonzalez A. Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study. Arthritis Res Ther. 2006;8:R1. http://arthritis-research.com/content/8/1/R1
  28. McQuibban GA, Gong JH, Tam EM et al. Inflammation dampened by gelatinase A cleavageof monocyte chemoattractant protein-3. Science. 2000;289:1202-1206.
  29. McQuibban GA, Butler GS, Gong JH et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem. 2001;276:43503-43508.
  30. Itoh T, Matsuda H, Tanioka M et al. The Role of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in Antibody-Induced Arthritis. J Immunol. 2002;169:2643-2647.
  31. Jovanovic DV, Martel-Pelletier J, Di Battista JA et al. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum. 2000;43(5):1134-1144.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies